sur Newron Pharmaceuticals S.p.A. (isin : IT0004147952)
Newron Pharmaceuticals Announces Board Nominee Changes
Newron Pharmaceuticals S.p.A. has announced proposed changes to its Board of Directors at the upcoming Annual General Meeting (AGM), scheduled for April 23, 2026. Patrick Langlois and Luca Benatti, who have long served on the Board, will step down. They are acknowledged for their significant contributions; Langlois served for 18 years, while Benatti was instrumental in the development of Xadago®, a treatment for Parkinson's disease.
New nominees George Garibaldi and Paolo Zocchi bring extensive experience. Garibaldi offers over 30 years in CNS drug development and has co-founded several biotech firms. Zocchi has 35 years in capital markets, with a background at Ernst & Young. Both are set to enhance Newron’s strategic direction with their expertise.
The full AGM agenda will be available on March 24, 2026, along with the 2025 full-year results and 2026 outlook, on Newron's website.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Newron Pharmaceuticals S.p.A.